CN108530433A - A kind of ester derivative and its application in preventing cardiovascular and cerebrovascular disease - Google Patents
A kind of ester derivative and its application in preventing cardiovascular and cerebrovascular disease Download PDFInfo
- Publication number
- CN108530433A CN108530433A CN201810550594.1A CN201810550594A CN108530433A CN 108530433 A CN108530433 A CN 108530433A CN 201810550594 A CN201810550594 A CN 201810550594A CN 108530433 A CN108530433 A CN 108530433A
- Authority
- CN
- China
- Prior art keywords
- ester derivative
- disease
- application
- formula
- vascular disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000002148 esters Chemical class 0.000 title claims abstract description 18
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 12
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 12
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- 210000004369 blood Anatomy 0.000 claims abstract description 10
- 239000008280 blood Substances 0.000 claims abstract description 10
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 9
- 208000019553 vascular disease Diseases 0.000 claims abstract description 8
- 210000001367 artery Anatomy 0.000 claims abstract description 6
- 208000032928 Dyslipidaemia Diseases 0.000 claims abstract description 5
- 238000008214 LDL Cholesterol Methods 0.000 claims abstract description 5
- 208000017170 Lipid metabolism disease Diseases 0.000 claims abstract description 5
- 208000018262 Peripheral vascular disease Diseases 0.000 claims abstract description 4
- 208000034189 Sclerosis Diseases 0.000 claims abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 4
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 3
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 claims description 4
- 102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 230000002491 angiogenic effect Effects 0.000 claims description 4
- 206010008118 cerebral infarction Diseases 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 208000037803 restenosis Diseases 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 208000031225 myocardial ischemia Diseases 0.000 claims description 3
- 239000012190 activator Substances 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims 1
- 101001130226 Homo sapiens Phosphatidylcholine-sterol acyltransferase Proteins 0.000 abstract description 14
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 abstract description 14
- 238000001994 activation Methods 0.000 abstract description 6
- 230000004913 activation Effects 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 5
- 238000002583 angiography Methods 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 32
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 28
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 28
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 20
- 239000002585 base Substances 0.000 description 16
- -1 Alcohol ester Chemical class 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- 235000019439 ethyl acetate Nutrition 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical class CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 229940125898 compound 5 Drugs 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 5
- 239000004327 boric acid Substances 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 101150003085 Pdcl gene Proteins 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 4
- 238000007872 degassing Methods 0.000 description 4
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- ZPPNULGEFMPRJO-UHFFFAOYSA-N 2,3-difluorothiophene Chemical compound FC=1C=CSC=1F ZPPNULGEFMPRJO-UHFFFAOYSA-N 0.000 description 3
- GZXDOXSIKJNUEW-UHFFFAOYSA-N 5-methylthiophene Chemical compound CC1=C=C[CH]S1 GZXDOXSIKJNUEW-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N CHCl3 Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 201000009101 diabetic angiopathy Diseases 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 241000282553 Macaca Species 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- JQRYUMGHOUYJFW-UHFFFAOYSA-N pyridine;trihydrobromide Chemical compound [Br-].[Br-].[Br-].C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1 JQRYUMGHOUYJFW-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- XGIKILRODBEJIL-UHFFFAOYSA-N 1-(ethylamino)ethanol Chemical compound CCNC(C)O XGIKILRODBEJIL-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000010152 Huntington disease-like 3 Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- GPWHDDKQSYOYBF-UHFFFAOYSA-N ac1l2u0q Chemical compound Br[Br-]Br GPWHDDKQSYOYBF-UHFFFAOYSA-N 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229950005953 camsilate Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- MRKZAZMYXYSBDG-UHFFFAOYSA-N cyclopentyl propanoate Chemical compound CCC(=O)OC1CCCC1 MRKZAZMYXYSBDG-UHFFFAOYSA-N 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000005956 quaternization reaction Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229950004288 tosilate Drugs 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A kind of application the invention discloses ester derivative and its in preventing cardiovascular and cerebrovascular disease,Wherein：R1、R2、R3It is independently selected from H, F or CH3.External LCAT activation experiments illustrate that the compounds of this invention has LCAT activations, internal effect experiment illustrates that the compounds of this invention can improve HDL levels, infers that the compounds of this invention can be used for preventing or treating cranial vascular disease, coronary heart disease, artery sclerosis, arteriography, peripheral vascular disease, dyslipidemia, low HDL cholesterolemia, high LDL cholesterol mass formed by blood stasis etc..
Description
Technical field
The invention belongs to chemical medicines, are related to a kind of ester derivative and its answering in preventing cardiovascular and cerebrovascular disease
With.
Background technology
Cardiovascular and cerebrovascular disease (cardiovascular and cerebrovascular diseases, CCVd) is heart
The general designation of blood vessel and cranial vascular disease refers to hyperlipidemia, blood is sticky, caused by atherosclerosis, hypertension etc.
Heart, brain and the body tissue ischemic or hemorrhagic disease that occur.Epidemiological study shows coronary heart disease (Coronary
Heart Disease, CHD) incidence in gradually rising trend, seriously affect population health, it has also become threaten human health
A big killer, more and more people are disabled lethal because of CHD.
Lecithin cholesterol acyltransferase (lecithin-cholesterolacyltransferase, LCAT) by
Liver synthesis is released into blood, exists in the form of dissociating or be combined with lipoprotein, is a kind of enzyme playing catalytic action in blood plasma,
It is that the positions the C2 unsaturated fatty acid of the lecithin of HDL is transferred to free cholesterol that it, which is acted on, generates lysolecithin and courage is solid
Alcohol ester.Almost 70%-80% is cholesteryl ester to plasma cholesterol, is caused by LCAT catalysis generates.LCAT is often incorporated in HDL
Together, very high in HDL granule surface activities and catalytic action, does not almost work to the particle of VLDL and LDL.LCAT is in people
Key player is play in the metabolism of class plasma cholesterol and HDL metabolism, there is weight for cardiovascular and cranial vascular disease prevention
Want meaning.
Invention content
The invention discloses a kind of ester derivative formula I, structure is：
Wherein：R1、R2、R3It is independently selected from H, F or CH3.The present invention also relates to
And the pharmaceutically acceptable salt or solvate of the ester derivative formula I.
Further, ester derivative formula I described in some preferred schemes is
The synthetic route that another object of the present invention discloses the ester derivative formula I is：
Specifically synthetic method is：
1) compound 1 reacts with cyclopentanone and generates 4- (the amyl- 1- alkene -1- bases of ring) -1H- pyrroles under strongly alkaline conditions
Cough up -2- carboxylic acids (compound 2)；
2) compound 2 is at Pd (OH)2/ C is as catalyst, 1:1 THF-MeOH under the action of solvent as hydrogenating
Reaction generates 4- cyclopenta -1H- pyrroles -2- carboxylic acids (compound 3)；
3) esterification occurs under the action of thionyl chloride, ethyl alcohol for the carboxyl in compound 3, generates 4- cyclopenta -1H-
Pyrroles -2- carboxylic acid, ethyl esters (compound 4)；
4) the substitution reaction generation bromo- 4- cyclopenta -1H- pyrroles -2- carboxylics of 5- occur under the action of bromide reagent for compound 4
Acetoacetic ester (compound 5)；
5) under alkaline condition, compound 5 reacts with corresponding boric acid, generates final product.
Further, the highly basic in the step 1) can be alkali metal hydroxide, alkali metal alcoholates or alkali metal
Hydride in a solvent, preferred as alkali alkoxide, most preferably sodium methoxide.
Further, suitable bromide reagent includes elemental bromine, N-bromosuccinimide, tribromide in the step 4)
Pyridine, dibromo hydantoins and corresponding iodo derivative, preferably pyridinium tribromide.
Further, the alkali in the step 5) can be sodium carbonate, potassium carbonate or potassium acetate etc., preferably sodium carbonate.
Another object of the present invention discloses the ester derivative formula I and swashs as lecithin cholesterol acyltransferase
The application of agent living.
Another object of the present invention discloses I answering in the drug for preparing cardiovascular and cerebrovascular disease of the ester derivative formula
With.
Further, the ester derivative formula I for prevent or treat cranial vascular disease (including apoplexy and cerebral infarction),
Coronary heart disease (including heart failure, myocardial infarction, angina pectoris, myocardial ischemia, cardiovascular disorder and angiogenic restenosis) is moved
Arteries and veins hardening, arteriography, peripheral vascular disease (including diabetic vascular complications), dyslipidemia, low HDL courage
Sterol mass formed by blood stasis, high LDL cholesterol mass formed by blood stasis etc..
Pharmaceutically acceptable salt of the present invention refers to the organic salt and inorganic salts of the compounds of this invention.Pharmaceutically may be used
The salt that the nontoxic acid received is formed includes, but is not limited to, inorganic acid salt, such as hydrochloride, hydrobromate, phosphate, sulfuric acid
Salt, perchlorate；Acylate, such as acetate, oxalates, maleate, tartrate, citrate, succinate, the third two
Hydrochlorate；Or these salt are obtained by other methods described in the books or literature such as ion-exchange.Other can pharmaceutically connect
The salt received includes adipate, alginates, ascorbate, aspartate, benzene sulfonate, benzoate, bisulphate,
Borate, butyrate, camphor hydrochlorate, camsilate, cyclopentyl propionate, digluconate, lauryl sulfate, second
Sulfonate, formates, fumarate, gluceptate, glycerophosphate, gluconate, Hemisulphate, enanthate,
Caproate, hydriodate, 2- hydroxy-ethanesulfonate salts, lactobionate, lactate, laruate, lauryl sulfate, apple
Hydrochlorate, mesylate, 2- naphthalene sulfonates, nicotinate, nitrate, oleate, palmitate, pamoate, pectate, persulfuric acid
Salt, 3- phenylpropionic acid salt, picrate, pivalate, propionate, stearate, rhodanate, tosilate, 11
Hydrochlorate, valerate, etc..By including alkali metal, alkaline-earth metal, ammonium and N+ (C1-4 alkane with alkali appropriate salt obtained by the reaction
Base) 4 salt.Water-soluble or oil-soluble or dispersion product can be obtained by quaternization.Can with the alkali metal of forming salt or
Alkaline-earth metal includes sodium, lithium, potassium, calcium, magnesium, etc..Pharmaceutically acceptable salt further comprises appropriate, nontoxic ammonium, season
The amine cation that ammonium salt and gegenions are formed, such as halide, hydroxide, carboxylate, hydrosulphate, phosphoric acid compound, nitre
Acidulants, C1-8 azochlorosulfonate acid compounds and aromatic sulphonic acid compound.
Solvate of the present invention refers to that one or more solvent molecules are formed by with the compound of the present invention and form
Close object.The solvent for forming solvate includes, but is not limited to, water, isopropanol, ethyl alcohol, methanol, dimethyl sulfoxide, ethyl acetate,
Acetic acid and ethylaminoethanol.
Specific embodiment
Embodiment 1：The synthesis of 4- cyclopenta -5- (4- fluorine thiophene -2- bases) -1H- pyrroles's -2- Ethyl formates
The synthesis of 1-1,4- (the amyl- 1- alkene -1- bases of ring) -1H- pyrroles's -2- carboxylic acids
Reflux condenser and mechanical agitator are equipped in the round-bottomed flask of 250mL, and whole system is purified with nitrogen.
1H- pyrroles -2- carboxylic acids (1.21g, 10.86mmol) are added in flask, MeOH (15.5mL) is then added.It stirs at room temperature
It mixes after ten minutes, cyclopentanone (2.88mL, 32.58mmol) is added.Methanol/sodium methoxide (25%w/ is added portionwise in 10 minutes
W, 15.15mL, 66.25mmol).Then the mixture is flowed back 24 hours.After being cooled to room temperature, water (23.31mL) is added simultaneously
Methanol is removed under reduced pressure.Remaining water phase is acidified to pH=1 with dense HCl (about 7mL).The pale yellow precipitate being collected by filtration
Object is washed with water and is dried in vacuo at 50 DEG C.Obtain required beige solid 4- (the amyl- 1- alkene -1- bases of ring) -1H- pyrroles -2-
Carboxylic acid (compound 2), 1.91g, yield 99%.1H-NMR(400MHz,CDCl3)δ:1.82(m,2H),2.31(m,2H),2.53
(t,2H),5.75(t,1H),7.02(s,1H),7.05(s,1H),9.03(s,1H).13C-NMR(125MHz,CDCl3)δ:
28.64,31.87,32.20,114.52,116.02,123.12,124.28,128.48,141.40,160.97.LC-MS(ESI,
pos,ion)m/z:178[M+H].
The synthesis of 1-2,4- cyclopenta -1H- pyrroles's -2- carboxylic acids
Unsaturated compound 2 (1.91g, 10.75mmol) obtained above is placed under 50psi Hydrogen Vapor Pressures and is hydrogenated
20 hours use 20%Pd (OH)2/ C is as catalyst, 1:1 THF-MeOH is as solvent.After filtration catalytic agent, decompression
Volatile matter is removed, residue is beaten with hexane.Beige solid is collected by filtration, washed with hexane and is dried in vacuo, obtains 4- rings penta
Base -1H- pyrroles -2- carboxylic acids (compound 3), 1.50g, yield 78%.1H-NMR(400MHz,CDCl3)δ:1.66(m,4H),
1.76(m,2H),1.92(m,2H),3.11(m,1H),7.05(s,1H),7.18(s,1H),8.87(s,1H).13C-NMR
(125MHz,CDCl3)δ:26.10,34.25,36.55,117.72,118.97,126.68,128.71,160.97.LC-MS
(ESI,pos,ion)m/z:180[M+H].
The synthesis of 1-3,4- cyclopenta -1H- pyrroles's -2- carboxylic acid, ethyl esters
Reflux condenser and mechanical agitator are equipped in the three-neck flask of 100mL, and whole system is purified with nitrogen.
Compound 3 (1.50g, 8.37mmol) is added in flask and is suspended in ethyl alcohol (13.58mL).Thionyl chloride is added dropwise
(1mL, 0.42mmol) and mixture is flowed back 24 hours.Volatile matter is removed under reduced pressure, residue is beaten with hexane, is washed with hexane
And obtain yellow solid 4- cyclopenta -1H- pyrroles -2- carboxylic acid, ethyl esters (compound 4), 1.53g, yield 88% after being dried in vacuo.1H-NMR(400MHz,CDCl3)δ:1.30(t,3H),1.66(m,4H),1.76(m,2H),1.92(m,2H),3.07(m,1H),
4.25(q,2H),6.88(s,1H),7.09(s,1H),8.81(s,1H).13C-NMR(125MHz,CDCl3)δ:14.68,
26.10,34.25,36.55,61.45,113.56,118.97,125.06,128.71,161.28.LC-MS(ESI,pos,ion)
m/z:208[M+H].
The synthesis of the bromo- 4- cyclopenta -1H- pyrroles -2- carboxylic acid, ethyl esters of 1-4,5-
Compound 4 (1.53g, 7.38mmol) is dissolved in THF (40mL) and CHCl3The in the mixed solvent of (40mL), then
Solution is cooled down in ice bath and pyridinium tribromide (2.95g, 9.23mmol) is added.After being stirred 1 hour at 0 DEG C, pass through TLC
Judge that reaction is completed.Use CHCl3(100mL) dilutes, and uses the NaHSO of 1mol/L successively3(2*25mL) is saturated NaHCO3(2*
25mL) aqueous solution and brine (25mL) washing.Use Na2SO4After drying, solvent is removed under reduced pressure, residue is tied from TBME- hexanes
It is brilliant.After being collected by filtration, after being washed and dried with hexane, the bromo- 4- cyclopenta -1H- pyrroles -2- carboxylic acid second of 5- of 1.45g red is obtained
Ester solid (compound 5).Red solid can be obtained after evaporation mother liquor, it (is used 15% by purified by flash chromatography
The hexane solution of EtOAc is as eluant, eluent), obtain other 0.34g compounds 5, total output 1.79g, yield 85%.1H-
NMR(400MHz,CDCl3)δ:1.30(t,3H),1.66(m,2H),1.67(m,2H),1.76(m,2H),1.93(m,2H),
3.08(m,1H),4.25(q,2H),6.74(s,1H),8.64(s,1H).13C-NMR(125MHz,CDCl3)δ:14.68,
26.10,34.69,40.95,61.45,109.52,119.08,126.51,132.33,161.64.LC-MS(ESI,pos,ion)
m/z:286[M+H].
The synthesis of 1-5,4- cyclopenta -5- (4- fluorine thiophene -2- bases) -1H- pyrroles's -2- Ethyl formates
By (4- fluorine thiophene -2- bases) boric acid (6.26mmol), compound 5 (1.79g, 6.26mmol), Na2CO3(2.00g,
18.78mmol), DME (10.14mL) and H2O (2.50mL) is added in 50mL microwave vials.Bottle N2Degassing 35 minutes, so
After PdCl is added2(dppf)CH2Cl2(0.55g, 0.75mmol) adduct.By microwave irradiation by reaction mixture at 120 DEG C
Heating 1 hour.Obtained mixture is diluted with ethyl acetate and is filtered by diatomite, is then concentrated in vacuo.Pass through quick color
Spectrometry purifies, and uses 0-100% ethyl acetate/heptanes as eluant, eluent, obtains off-white powder 4- cyclopenta -5- (4- fluorine thiophene -
2- yls) -1H- pyrroles's -2- Ethyl formates, 1.44g, yield 75%.1H-NMR(400MHz,CDCl3)δ:1.30(t,3H),1.66
(m,2H),1.68(m,2H),1.76(m,2H),1.93(m,2H),3.39(m,1H),4.25(q,2H),6.85(s,1H),7.06
(d,1H),7.40(d,1H),9.60(s,1H).13C-NMR(125MHz,CDCl3)δ:14.68,26.10,34.69,40.75,
61.45,113.04,118.61,120.05,125.08,128.49,129.53,138.94,161.62,161.64.LC-MS
(ESI,pos,ion)m/z:308[M+H]。
Embodiment 2：The synthesis of 4- cyclopenta -5- (5- fluorine thiophene -2- bases) -1H- pyrroles's -2- Ethyl formates
By (5- fluorine thiophene -2- bases) boric acid (6.26mmol), compound 5 (1.79g, 6.26mmol), Na2CO3(2.00g,
18.78mmol), DME (10.14mL) and H2O (2.50mL) is added in 50mL microwave vials.Bottle N2Degassing 35 minutes, so
After PdCl is added2(dppf)CH2Cl2(0.55g, 0.75mmol) adduct.By microwave irradiation by reaction mixture at 120 DEG C
Heating 1 hour.Obtained mixture is diluted with ethyl acetate and is filtered by diatomite, is then concentrated in vacuo.Pass through quick color
Spectrometry purifies, and uses 0-100% ethyl acetate/heptanes as eluant, eluent, obtains off-white powder 4- cyclopenta -5- (5- fluorine thiophene -
2- yls) -1H- pyrroles's -2- Ethyl formates, 1.50g, yield 78%.LC-MS(ESI,pos,ion)m/z:308[M+H].
Embodiment 3：The synthesis of 4- cyclopenta -5- (5- methylthiophene -2- bases) -1H- pyrroles's -2- Ethyl formates
By (5- methylthiophene -2- bases) boric acid (6.26mmol), compound 5 (1.79g, 6.26mmol), Na2CO3
(2.00g, 18.78mmol), DME (10.14mL) and H2O (2.50mL) is added in 50mL microwave vials.Bottle N2Degassing 35
Minute, PdCl is then added2(dppf)CH2Cl2(0.55g, 0.75mmol) adduct.By microwave irradiation by reaction mixture
It is heated 1 hour at 120 DEG C.Obtained mixture is diluted with ethyl acetate and is filtered by diatomite, is then concentrated in vacuo.Pass through
Purified by flash chromatography uses 0-100% ethyl acetate/heptanes as eluant, eluent, obtains off-white powder 4- cyclopenta -5- (5-
Methylthiophene -2- bases) -1H- pyrroles's -2- Ethyl formates, 1.29g, yield 68%.LC-MS(ESI,pos,ion)m/z:304[M+
H]。
Embodiment 4：The synthesis of 4- cyclopenta -5- (4,5- difluoro thiophene -2- bases) -1H- pyrroles's -2- Ethyl formates
By (4,5- difluoro thiophene -2- bases) boric acid (6.26mmol), compound 5 (1.79g, 6.26mmol), Na2CO3
(2.00g, 18.78mmol), DME (10.14mL) and H2O (2.50mL) is added in 50mL microwave vials.Bottle N2Degassing 35
Minute, PdCl is then added2(dppf)CH2Cl2(0.55g, 0.75mmol) adduct.By microwave irradiation by reaction mixture
It is heated 1 hour at 120 DEG C.Obtained mixture is diluted with ethyl acetate and is filtered by diatomite, is then concentrated in vacuo.Pass through
Purified by flash chromatography uses 0-100% ethyl acetate/heptanes as eluant, eluent, obtain off-white powder 4- cyclopenta -5- (4,
5- difluoro thiophene -2- bases) -1H- pyrroles's -2- Ethyl formates, 1.61g, yield 79%.LC-MS(ESI,pos,ion)m/z:326
[M+H]。
Test example 1：External LCAT activation experiments
One, experimental program
By density gradient centrifugation separation the part (1.125 being made of HDL3 is obtained from the blood plasma of the people of health<Proportion<
1.210/mL).By the part of acquisition to phosphate-buffered saline (pH 7.4) dialysis and as LCAT enzyme source and receptor.
Each testing drug is prepared by being dissolved in dimethyl sulfoxide (DMSO).DTNB (Ellman reagents, ultimate density will be contained：0.5mM), sulfydryl second
Alcohol (ultimate density：12.5mM) and [14C] cholesterol of 0.6% bovine serum albumin(BSA) is added to the phosphoric acid containing 1mg/mLHDL3
Salt-buffered saline (pH 7.4), and the testing drug of various concentration is further added to so that total amount is adjusted to 80 μ L.37
DEG C cultivate the mixture about 16 hours.Then, mixed solution (mixing ratio=3 of hexane and isopropanol are added to:2) to stop
Reaction.After stirring, hexane layer is collected, and evaporates the layer to dry.It is added to chloroformic solution (concentration：10mg/mL), it and will mix
Object point dye is closed on thin layer silica gel plate, and uses mixed solution (mixing ratio=85 of hexane, diethyl ether and ethyl acetate:15:2)
Expansion.Using imaging analysis instrument BAS-2500 (Fujifilm Corp. are manufactured), the part corresponding to cholesterol acid ester is measured
Radioactivity.It is similarly processed and analyzes the sample for not supplementing testing drug.According to expression formula given below, relative to not mending
The LCAT activity for filling the sample of testing drug, calculates the EC of LCAT activation50。
Equation：
The bottoms Y=+(Top-Bottom)/(1+10LogEC-X)
Wherein X represents the logarithm of the concentration of testing drug；
Y represents the response (LCAT activity) of testing drug；
Top represents maximum value (maximum platform)；
Bottom represents minimum value (minimum platform)；
EC50Represent 50% effective concentration.
Two, experimental result
The results are shown in table below for external LCAT activation experiments：
| Number | EC50(nM) |
| SDK1001 | 68.3 |
| SDK1002 | 67.5 |
| SDK1003 | 63.1 |
| SDK1004 | 58.5 |
| SDK1005 | 67.0 |
| SDK1006 | 67.3 |
| SDK1007 | 57.6 |
| SDK1008 | 56.1 |
| SDK1009 | 57.3 |
| SDK1010 | 64.2 |
As can be seen from the above table, the compounds of this invention has LCAT activations, LCAT activator can be used as pre-
Anti- or treatment cranial vascular disease (including apoplexy and cerebral infarction), coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac muscle
Ischemic, cardiovascular disorder and angiogenic restenosis), artery sclerosis, arteriography, peripheral vascular disease
(including diabetic vascular complications), dyslipidemia, low HDL cholesterolemia, high LDL cholesterol mass formed by blood stasis etc..
Test example 2：Internal effect experiment
One, experimental program
Each testing drug is dissolved in propylene glycol:The mixed solution of Tween 80=4/1 (v/v), and macaque is administered orally
The solution 1 or 7 days.The the 1st or the 7th day during administration, blood is collected later with administration before administration, and obtain blood plasma.
It is surveyed using commercially available assay kit (cholesterol-E Wako, Wako Pure Chemical Industries, Ltd.)
Measure the cholesterol level in blood plasma.Lipoprotein, which is analyzed, by HPLC is distributed (column：LipopropakXL, Tosoh Corp. systems
It makes).HDL cholesterol and non-HDL cholesterol levels are calculated according to following calculation expression：
Cholesterol level × (HDL cholesterol peak area/peak summation) in HDL cholesterol levels=blood plasma
Cholesterol level × (peak area of non-HDL cholesterol/peak summation) two in non-HDL cholesterol levels=blood plasma,
Experimental result
10mg/kg single doses are only disclosed in experimental result of the present invention, and the variation of HDL levels for 24 hours is administered after preceding and administration,
To prove that the ability of HDL in the compounds of this invention raising macaque blood, more experimental datas do not disclose in the present invention.With to
It is compared before medicine, the increment rate (%) of HDL levels is by before being administered and 24 hours after administration after the administration of 10mg/kg single doses
AUC determine.
| Number | Increment rate (%) |
| SDK1001 | 357.1 |
| SDK1002 | 346.8 |
| SDK1003 | 341.0 |
| SDK1004 | 399.9 |
| SDK1005 | 359.8 |
| SDK1006 | 363.0 |
| SDK1007 | 381.6 |
| SDK1008 | 409.7 |
| SDK1009 | 334.8 |
| SDK1010 | 301.9 |
As can be seen from the above table, the compounds of this invention can improve HDL horizontal forces, can to preventing or treating following disease
Can have positive effect, cranial vascular disease (including apoplexy and cerebral infarction), coronary heart disease (including heart failure, myocardial infarction, the heart twist
Bitterly, myocardial ischemia, cardiovascular disorder and angiogenic restenosis), artery sclerosis, arteriography, peripheral blood
Pipe disease (including diabetic vascular complications), dyslipidemia, low HDL cholesterolemia, high LDL cholesterol mass formed by blood stasis etc..
Claims (6)
1. a kind of general formula structure is the ester derivative and its pharmaceutically acceptable salt or solvate of formula I
Wherein：R1、R2、R3It is independently selected from H, F or CH3。
2. ester derivative formula I as described in claim 1, characterized in that be selected from following compound：
3. the answering as lecithin cholesterol acyltransferase activator of ester derivative formula I as claimed in claim 1 or 2
With.
4. application of the ester derivative formula I as claimed in claim 1 or 2 in the drug for preparing cardiovascular and cerebrovascular disease.
5. ester derivative formula I as claimed in claim 1 or 2 is preparing cranial vascular disease, coronary heart disease, artery sclerosis, artery
Hardenability heart disease, peripheral vascular disease, dyslipidemia, low HDL cholesterolemia, high LDL cholesterol mass formed by blood stasis drug in
Application.
6. application as claimed in claim 5, which is characterized in that the cranial vascular disease includes apoplexy and cerebral infarction, the hat
Worry includes heart failure, myocardial infarction, angina pectoris, myocardial ischemia, cardiovascular disorder and angiogenic restenosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810550594.1A CN108530433A (en) | 2018-05-31 | 2018-05-31 | A kind of ester derivative and its application in preventing cardiovascular and cerebrovascular disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810550594.1A CN108530433A (en) | 2018-05-31 | 2018-05-31 | A kind of ester derivative and its application in preventing cardiovascular and cerebrovascular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108530433A true CN108530433A (en) | 2018-09-14 |
Family
ID=63473517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810550594.1A Withdrawn CN108530433A (en) | 2018-05-31 | 2018-05-31 | A kind of ester derivative and its application in preventing cardiovascular and cerebrovascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108530433A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105873928A (en) * | 2013-12-13 | 2016-08-17 | 第三共株式会社 | 5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative |
| CN106916143A (en) * | 2017-03-14 | 2017-07-04 | 哈尔滨医科大学 | A kind of medicine for preventing and treating coronary heart disease and its application |
-
2018
- 2018-05-31 CN CN201810550594.1A patent/CN108530433A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105873928A (en) * | 2013-12-13 | 2016-08-17 | 第三共株式会社 | 5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative |
| CN106916143A (en) * | 2017-03-14 | 2017-07-04 | 哈尔滨医科大学 | A kind of medicine for preventing and treating coronary heart disease and its application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104262267B9 (en) | PGI2 receptor modulators for the treatment of prostacyclin (PGI2) receptor related disorders | |
| DE69331954T2 (en) | SQUALEN SYNTHASE INHIBITORS WITH CYCLOALKYLAMINE TO ARYL STRUCTURE | |
| EP2760878B1 (en) | Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments | |
| CA3028207A1 (en) | Preparation, uses and solid forms of obeticholic acid | |
| EP0129906A1 (en) | Phenoxyalkoxy-3,4-dihydro-2H-1-benzopyran derivatives | |
| TW200817311A (en) | New CXCR2 inhibitors | |
| DE3049039A1 (en) | USE OF BENZOCHINONE DERIVATIVES FOR TREATING ISCHEMIC DISEASES AND MEDICINAL COMPOUNDS THEREFOR | |
| JP2012519193A (en) | Tetrahydro-imidazo [1,5-α] pyrazine derivative salt, production method thereof and pharmaceutical use | |
| CN108752245A (en) | Naphthalene sulfonylamide acetamides and its application and pharmaceutical composition | |
| Zhong et al. | Design, synthesis and biological evaluations of diverse Michael acceptor-based phenazine hybrid molecules as TrxR1 inhibitors | |
| CN108530433A (en) | A kind of ester derivative and its application in preventing cardiovascular and cerebrovascular disease | |
| CN108658830A (en) | A kind of ester derivative and its application in preventing cardiovascular and cerebrovascular disease | |
| CN108558847A (en) | A kind of ester derivative and its application in preventing cardiovascular and cerebrovascular disease | |
| CN108530334A (en) | A kind of ester derivative and its application in preventing cardiovascular and cerebrovascular disease | |
| CN108822079A (en) | A kind of ester derivative and its application in prevention and treatment cardiovascular and cerebrovascular disease | |
| JP5903166B2 (en) | Derivatives of butylphthalide and methods for producing and using the same | |
| CN108840856A (en) | A kind of ester derivative and its application in prevention and treatment cardiovascular and cerebrovascular disease | |
| CN106916143A (en) | A kind of medicine for preventing and treating coronary heart disease and its application | |
| JPS63152379A (en) | 17,18-dehydro-apovinkaminol | |
| CN109206470B (en) | Preparation method of echinocystic acid derivative and new medicinal use | |
| JPH0514708B2 (en) | ||
| CN104356120A (en) | Polysubstitution quinolines pitavastatin lactone dewatering compound and application thereof | |
| US4665214A (en) | 15(R+S)-fluoro-11,15-dideoxyprostaglandin E1 derivatives | |
| CN107074744B (en) | Nep inhibitor crystal type free acid, calcium salt polymorphic and its preparation method and application | |
| JPS591452A (en) | Synthesis of 2-diethylamino-1-methylethyl- cis-1-hydroxy-(bicyclohexyl)-2-carboxylate derivatives and compounds thereby |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180914 |
|
| WW01 | Invention patent application withdrawn after publication |